ArticleIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
Role of 6-Fluoro-18F-l-3,4-DOPA MR-PET in Clinical Workup in Movement Disorders Cases: An Exploratory Study in a Tertiary Care Neuropsychiatric Setup.
Article in Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 6-Fluoro-18F-l-3,4-dihydroxyphenylalanine (18F-DOPA) is primarily used to differentiate nondopamine deficient symptomatic subjects from Parkinsonian disorders and various etiologies from one another, which otherwise can be challenging. The current study aimed to determine (18F)-DOPA positron emission tomography (PET) patterns in Idiopathic Parkinson's disease (IPD), nondopamine deficient symptomatic (NDDS) and other movement disorders. Materials and Methods: Sixty patients referred from neuropsychiatric outpatient department were retrospectively analyzed who underwent (18F)-DOPA magnetic resonance (MR)-PET scans. Out of 60 subjects, 36 were diagnosed with IPD, 5 were cases of other movement disorders, and 19 were normal on PET imaging (NDDS). To evaluate and quantify the tracer uptake from the PET scans, a region of interest (ROI) was drawn on the least radiotracer uptake region, and subsequently, on bilateral occipital cortex, caudate (head, body, tail), putamen (anterior, posterior), periaqueductal gray matter and red nucleus using structural MR images (MRI) for better delineation of anatomical regions. Tracer uptake ratios from each selected region were generated as SUV Results: The posterior putamen showed a significant difference between IPD and other patients with an SUV cutoff of 1.69 and 100% specificity and 99.2% accuracy for normal controls. Whereas, we observed an SUV cutoff of 1.75 and an accuracy and specificity of 100% in patients with other movement disorders. The absolute values from the caudate nucleus were demonstrating a statistical significance between other movement disorders compared to normal controls with a cutoff of 1.69 and an accuracy of 81.2%. The ratio of posterior putamen/occipital ratio was significant between IPD and normal controls, with a cutoff of 3.89 and an accuracy of 95.6%. Right caudate to occipital ratio (RCOR) was significant for differentiating between other movement disorders and normal controls with a cutoff of 3.01 and an accuracy of 95.6%. One novel finding was that occipital lobe uptake was significantly reduced in patients with IPD compared to other movement disorders. Conclusion: The findings from the current study demonstrated that hybrid imaging using 18F-DOPA PET/MRI could efficiently differentiate between various causes of Parkinson's disease with diagnostic accuracy and necessary cut-offs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.